F
Franz O. Smith
Researcher at National Institutes of Health
Publications - 14
Citations - 2852
Franz O. Smith is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Tumor-infiltrating lymphocytes & Survival rate. The author has an hindex of 10, co-authored 13 publications receiving 2621 citations. Previous affiliations of Franz O. Smith include Moffitt Cancer Center & University of South Florida.
Papers
More filters
Journal ArticleDOI
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley,James Chih-Hsin Yang,Richard M. Sherry,Michael S. Hughes,Richard E. Royal,Udai S. Kammula,Paul F. Robbins,Jian Ping Huang,Deborah Citrin,Susan F. Leitman,John R. Wunderlich,Nicholas P. Restifo,Armen A. Thomasian,Stephanie G. Downey,Franz O. Smith,Jacob A. Klapper,Kathleen E. Morton,Carolyn M. Laurencot,Donald E. White,Steven A. Rosenberg +19 more
TL;DR: Host lymphodepletion followed by autologous TIL transfer and IL-2 results in objective response rates of 50% to 70% in patients with metastatic melanoma refractory to standard therapies.
Journal ArticleDOI
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G. Downey,Jacob A. Klapper,Franz O. Smith,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Udai S. Kammula,Michael S. Hughes,Tamika Allen,Catherine Levy,Michael Yellin,Geoffrey M. Nichol,Donald E. White,Seth M. Steinberg,Steven A. Rosenberg +14 more
TL;DR: In patients with metastatic melanoma, ipilimumab can induce durable objective clinical responses, which are related to the induction of IRAEs, and this work shows that CTLA-4 blockade can inhibit T-cell activation and helps maintain peripheral self-tolerance.
Journal ArticleDOI
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
Jacob A. Klapper,Stephanie G. Downey,Franz O. Smith,James Chih-Hsin Yang,Michael S. Hughes,Udai S. Kammula,Richard M. Sherry,Richard E. Royal,Seth M. Steinberg,Steven A. Rosenberg +9 more
TL;DR: The treatment of metastatic renal cell carcinoma with high‐dose interleukin‐2 (HD IL‐2) has resulted in durable tumor regression in a minority of patients, and the authors' 20‐year experience administering this immunotherapeutic agent is presented.
Journal ArticleDOI
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Franz O. Smith,Stephanie G. Downey,Jacob A. Klapper,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Udai S. Kammula,Michael S. Hughes,Nicholas P. Restifo,Catherine Levy,Donald E. White,Seth M. Steinberg,Steven A. Rosenberg +12 more
TL;DR: IL-2 can produce a modest response rate in patients with metastatic melanoma including patients with durable complete responses, and vaccination with gp100:209-217(210M) peptide was associated with significant increase in response rates.
Journal ArticleDOI
Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL
Stephanie L. Goff,Franz O. Smith,Jacob A. Klapper,Richard M. Sherry,John R. Wunderlich,Seth M. Steinberg,Donald E. White,Steven A. Rosenberg,Mark E. Dudley,James Chih-Hsin Yang +9 more
TL;DR: This compendium may provide a framework for therapeutic decision making and future investigation in adoptive transfer of tumor-infiltrating lymphocytes, as more centers begin exploring the use of adoptive transfer with TIL.